Literature DB >> 33990152

18F-FDG PET/CT features of ureteral metastases from breast cancer: a case report.

Yuanbi Huang1, Huajie He1, Wei Wei2, Qiguang Li1, Xian Long1, Yongpeng Li1, Rongchao Chen1, Xianlin Yi1.   

Abstract

Breast cancer metastasis to the ureter is rare. Fluorine-18-fluorodeoxyglucose positron emission tomography (18F-FDG PET)/computed tomography (CT) is widely used to identify primary lesions of metastatic tumours, however, 18F-FDG PET/CT imaging features of ureteral metastasis from breast cancer are rarely reported. Herein, the case of a 46-year-old woman with recurrent left flank pain for 5 months, who was admitted to the Cancer Hospital of Guangxi Medical University and Guangxi Cancer Research Institute, is described. She had undergone right radical mastectomy 5 years previously and had received tamoxifen treatment for 5 years. Assessment by 18F-FDG PET/CT revealed tumours on the ureter presenting as a long segmental lesion, radioactive concentrations, and a low maximum standardized uptake value (SUVmax), with no radioactive concentrations in the urine and no significant change in the ureteral contour. The severity of the ureteral lesion was not consistent with the severity of hydronephrosis. A tumour biopsy was performed laparoscopically, and postoperative pathological examination confirmed a primary breast cancer tumour. The patient did not consent to treatment and was lost to follow-up.

Entities:  

Keywords:  18F-FDG PET/CT features; Breast cancer; case report; metastasis; mild hydronephrosis; ureteral metastatic carcinoma

Year:  2021        PMID: 33990152     DOI: 10.1177/03000605211014090

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  1 in total

1.  Diagnostic and Therapeutic Challenges in a Patient with Ureteral Metastases from a Triple Negative Breast Cancer.

Authors:  Georgia Saranti; Vasiliki Zolota; Christina Kalogeropoulou; Nikolaos Papathanasiou; Theodora Katsila; Konstantina Kitsou; Ilias Haliassos; Dimitrios Kardamakis
Journal:  Curr Oncol       Date:  2022-07-07       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.